Analyst firms · Piper Sandler · DXCM

Piper Sandler DXCM price target and rating history

DexCom Inc. (DXCM) · Health Care

Piper Sandler rates DexCom Inc. (DXCM) Overweight with a $750 price target, as of its latest action on Nov 3, 2021. It has published 3 rating actions on DXCM since July 2021, including 0 upgrades and 0 downgrades. Across 5 firms with a DXCM price target in the last 12 months, the median target is $86.

Current rating
Overweight
Price target
$750
Median target, all firms
$86
Actions on DXCM
3

Piper Sandler price target on DXCM

$750$650$55020222023202420252026
Piper Sandler price target on DXCM, each point a stated target, July 2021 to November 2021.

Every Piper Sandler rating on DXCM

How other firms rate DXCM

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
BarclaysOverweight$115Oct 7, 2026
Deutsche BankBuy$86Jun 23, 2026
The Benchmark CompanyBuy$77May 12, 2026
Evercore ISIOutperform$90Mar 24, 2026
Morgan StanleyOverweight$75Dec 2, 2025

Questions about Piper Sandler and DXCM

What is Piper Sandler's price target for DXCM?
Piper Sandler's latest stated price target for DexCom Inc. (DXCM) is $750, from its action on Nov 3, 2021.
What is Piper Sandler's rating on DXCM?
Piper Sandler rates DXCM Overweight, a bullish rating, as of Nov 3, 2021.
When did Piper Sandler last change its view on DXCM?
On Nov 3, 2021, Piper Sandler raises its price target to $750 from $675, keeps Overweight.
How does Piper Sandler's DXCM target compare with other analysts?
Across 5 firms with a DXCM price target in the last 12 months, the median target is $86.

More DXCM rating histories

All Piper Sandler ratingsDXCM news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.